Citations

Showing 10 of 108119 citations.

Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis
Muchtar, Eli , Koehler, Amber B. , Johnson, Michael , Rabe, Kari G. , Ding, Wei , Call, Timothy G. , Leis, José F., Kenderian, Saad S. , Hayman, Suzanne R. , Wang, Yucai , Hampel, Paul J. , Holets, Matthew, Darby, Heather C., Miao, Congrong, Canniff, Jennifer, Whitaker, Jennifer A. , Levin, Myron J. , Schmid, D. Scott , Kennedy, Richard B. , Weinberg, Adriana , Holets, Matthew A, Parikh, Sameer A , Chaffee, Kari G. , Kenderian, Saad Sirop , Ding, Wei , Muchtar, E , Koehler, Amber B , Wang, Yucai , Kennedy, Richard , Slager, Susan L. , Kay, Neil E. , Parikh, Sameer A.

Mayo Clinic

American Journal of Hematology | October 26, 2021 | Volume: 97 | Issue: 1 | Pages: 90-98

10.1002/ajh.26388 | PMID 34699616 Get It

AbstractMonoclonal B‐cell lymphocytosis (MBL) and chronic lymphocytic leukemia (CLL) are clonal B‐cell disorders associated with an increased risk of infections and impaired vaccination responses. We investigated the immunogenicity of recombinant zoster vaccine (RZV) in these patients. Individuals with MBL/untreated CLL and Bruton tyrosine kinase inhibitor (BTKi)‐treated CLL patients were given two doses of RZV separated by 2 months. Responses assessed at 3 and 12 months from the first dose of RZV by an anti‐glycoprotein E ELISA antibody assay and by dual‐color Interferon‐γ and Interleukin‐2FLUOROSPOT assays were compared to historic controls matched by age and sex. About 62 patients (37 MBL/untreated CLL and 25 BTKi‐treated CLL) were enrolled with a median age of 68 years at vaccination. An antibody response at 3 months was seen in 45% of participants, which was significantly lower compared to historic controls (63%, p = .03). The antibody response did not significantly differ between MBL/untreated CLL and BTKi‐treated CLL (51% vs. 36%, respectively, p = .23). The CD4+ T‐cell response to vaccination was significantly lower in study participants compared to controls (54% vs. 96%, p < .001), mainly due to lower responses among BTKi‐treated patients compared to untreated MBL/CLL (32% vs. 73%, p = .008). Overall, only 29% of participants achieved combined antibody and cellular responses to RZV. Among participants with response assessment at 12 months (n = 47), 24% had antibody titers below the response threshold. Hypogammaglobulinemia and BTKi therapy were associated with reduced T‐cell responses in a univariate analysis. Strategies to improve vaccine response to RZV among MBL/CLL patients are needed.
Systematic Review and Meta-analysis of Acute Treatments for Episodic Migraine in Adults—Reply
Wang, Zhen , VanderPluym, Juliana H. , Murad, M. Hassan , Murad, Mohammad Hassan

Mayo Clinic

JAMA | October 26, 2021 | Volume: 326 | Issue: 16 | Pages: 1637

10.1001/jama.2021.14069 | PMID 34698787 Get It

Phase II Randomized Trial of Transoral Surgery and Low-Dose Intensity Modulated Radiation Therapy in Resectable p16+ Locally Advanced Oropharynx Cancer: An ECOG-ACRIN Cancer Research Group Trial (E3311)
Ferris, Robert L. , Flamand, Yael, Weinstein, Gregory S., Li, Shuli, Quon, Harry , Mehra, Ranee , Garcia, Joaquin J., Chung, Christine H. , Gillison, Maura L., Duvvuri, Umamaheswar, O'Malley, Bert W., Ozer, Enver, Thomas, Giovana R., Koch, Wayne M., Bell, R. Bryan , Lango, Miriam N. , Méndez, Eduardo, Burtness, Barbara , Gross, Neil D , Bell, R Bryan , Saba, Nabil F , Lango, Miriam , Burtness, Barbara , Quon, Harry , Ferris, Robert L , Flamand, Yael, Weinstein, Gregory S., Li, Shuli, Mehra, Ranee , Garcia, Joaquin J., Chung, Christine H. , Gillison, Maura L., Duvvuri, Umamaheswar, O'Malley, Bert W., Ozer, Enver, Thomas, Giovana R., Koch, Wayne M., Méndez, Eduardo

Mayo Clinic

Journal of Clinical Oncology | October 26, 2021 | Volume: 40 | Issue: 2 | Pages: 138-149

10.1200/jco.21.01752 | PMID 34699271 Get It

PURPOSE Definitive or postoperative chemoradiation (CRT) is curative for human papillomavirus–associated (HPV+) oropharynx cancer (OPC) but induces significant toxicity. As a deintensification strategy, we studied primary transoral surgery (TOS) and reduced postoperative radiation therapy (RT) in intermediate-risk HPV+ OPC. METHODS E3311 is a phase II randomized trial of reduced- or standard-dose postoperative RT for resected stage III-IVa (American Joint Committee on Cancer-seventh edition) HPV+ OPC, determined by pathologic parameters. Primary goals were feasibility of prospective multi-institutional study of TOS for HPV+ OPC, and oncologic efficacy (2-year progression-free survival) of TOS and adjuvant therapy in intermediate-risk patients after resection. TOS plus 50 Gy was considered promising if the lower limit of the exact 90% binomial confidence intervals exceeded 85%. Quality of life and swallowing were measured by functional assessment of cancer therapy-head and neck and MD Anderson Dysphagia Index. RESULTS Credentialed surgeons performed TOS for 495 patients. Eligible and treated patients were assigned as follows: arm A (low risk, n = 38) enrolled 11%, intermediate risk arms B (50 Gy, n = 100) or C (60 Gy, n = 108) randomly allocated 58%, and arm D (high risk, n = 113) enrolled 31%. With a median 35.2-month follow-up for 359 evaluable (eligible and treated) patients, 2-year progression-free survival Kaplan-Meier estimate is 96.9% (90% CI, 91.9 to 100) for arm A (observation), 94.9% (90% CI, 91.3 to 98.6]) for arm B (50 Gy), 96.0% (90% CI, 92.8 to 99.3) for arm C (60 Gy), and 90.7% (90% CI, 86.2 to 95.4) for arm D (66 Gy plus weekly cisplatin). Treatment arm distribution and oncologic outcome for ineligible or step 2 untreated patients (n = 136) mirrored the 359 evaluable patients. Exploratory comparison of functional assessment of cancer therapy-head and neck total scores between arms B and C is presented. CONCLUSION Primary TOS and reduced postoperative RT result in outstanding oncologic outcome and favorable functional outcomes in intermediate-risk HPV+ OPC.
Characterization of Postural Sway in Patients With Persistent Postural-Perceptual Dizziness (PPPD) Using Wearable Motion Sensors
McCaslin, Devin L., Shepard, Neil T., Hollman, John H., Staab, Jeffrey P., McCaslin, Devin L., Shepard, Neil T., Hollman, John H., Staab, Jeffrey P.

Mayo Clinic

Otology & Neurotology | October 26, 2021 | Volume: 43 | Issue: 2 | Pages: e243-e251

10.1097/mao.0000000000003393 | PMID 34699399 Get It

Objective: To extend previous investigations of postural control in patients with persistent-postural perceptual dizziness (PPPD). Study Design: Case-controlled, cross-sectional, observational investigation. Setting: Tertiary care center. Patients: Fifteen patients with PPPD, 15 control volunteers. Interventions: Measurement of anterior-posterior (AP) and medial-lateral (ML) sway at the waist using wearable accelerometers during posturography; assessment of reach and gait. Main Outcome Measures: Peak-to-peak AP and ML sway displacement on the six conditions of the Sensory Organization Test (SOT); Scores on the SOT, Functional Reach Test (FRT), and Dynamic Gait Index (DGI). Results: Compared to control volunteers, patients with PPPD had significantly greater sway displacement at the waist in the AP direction in SOT conditions 3, 5, and 6 and in the ML direction in SOT conditions 2 and 4, resulting in significantly lower median equilibrium scores on the composite index and all six SOT conditions. Patients with PPPD had significantly lower scores on the FRT and DGI that were not correlated with SOT performance. AP sway in conditions 3 and 6 differentiated patients with PPPD from controls with high sensitivity (≥0.87) and specificity (≥0.87). Conclusions: This study replicated previous work showing poor SOT performance by patients with PPPD who had greater AP sway associated with visual dependence and greater ML sway in low demand conditions than controls. Patients with PPPD also performed poorer on the FRT and DGI, but lack of correlation with SOT scores suggested different mechanisms of impairment in postural control, reach, and ambulation. AP sway demonstrated potential as a diagnostic marker.
Molecular markers of risk of subsequent invasive breast cancer in women with ductal carcinoma in situ: protocol for a population-based cohort study
Rohan, Thomas E. , Ginsberg, Mindy , Wang, Yihong , Couch, Fergus J. , Feigelson, Heather Spencer , Greenlee, Robert T. , Honda, Stacey , Stark, Azadeh , Chitale, Dhananjay , Wang, Tao , Xue, Xiaonan , Oktay, Maja H. , Loudig, Olivier , Feigelson, Heather S , Sparano, Joseph A , Loudig, Olivier , Couch, Fergus J. , Wang, Yihong , Chitale, Dhananjay A , Sparano, Joseph A.

Mayo Clinic

BMJ Open | October 26, 2021 | Volume: 11 | Issue: 10 | Pages: e053397

10.1136/bmjopen-2021-053397 | PMID 34702732 Get It

Introduction Ductal carcinoma in situ (DCIS) of the breast is a non-obligate precursor of invasive breast cancer (IBC). Many DCIS patients are either undertreated or overtreated. The overarching goal of the study described here is to facilitate detection of patients with DCIS at risk of IBC development. Here, we propose to use risk factor data and formalin-fixed paraffin-embedded (FFPE) DCIS tissue from a large, ethnically diverse, population-based cohort of 8175 women with a first diagnosis of DCIS and followed for subsequent IBC to: identify/validate miRNA expression changes in DCIS tissue associated with risk of subsequent IBC; evaluate ipsilateral IBC risk in association with two previously identified marker sets (triple immunopositivity for p16, COX-2, Ki67; Oncotype DX Breast DCIS score); examine the association of risk factor data with IBC risk. Methods and analysis We are conducting a series of case–control studies nested within the cohort. Cases are women with DCIS who developed subsequent IBC; controls (2/case) are matched to cases on calendar year of and age at DCIS diagnosis. We project 485 cases/970 controls in the aim focused on risk factors. We estimate obtaining FFPE tissue for 320 cases/640 controls for the aim focused on miRNAs; of these, 173 cases/346 controls will be included in the aim focused on p16, COX-2 and Ki67 immunopositivity, and of the latter, 156 case–control pairs will be included in the aim focused on the Oncotype DX Breast DCIS score®. Multivariate conditional logistic regression will be used for statistical analyses. Ethics and dissemination Ethics approval was obtained from the Institutional Review Boards of Albert Einstein College of Medicine (IRB 2014-3611), Kaiser Permanente Colorado, Kaiser Permanente Hawaii, Henry Ford Health System, Mayo Clinic, Marshfield Clinic Research Institute and Hackensack Meridian Health, and from Lifespan Research Protection Office. The study results will be presented at meetings and published in peer-reviewed journals.
Pregnancy, Contraception, and Menopause in Advanced Chronic Kidney Disease and Kidney Transplant
Dines, Virginia , Parashuram, Santosh , Cosio, Fernando G., Kattah, Andrea G. , Dines, Virginia A, Kattah, Andrea G , Garovic, Vesna D.

Mayo Clinic

Women's Health Reports | October 26, 2021 | Volume: 2 | Issue: 1 | Pages: 488-496

10.1089/whr.2021.0053 | PMID 34841395 Get It

Reply to “Thinking beyond Aducanumab Controversy”
Petersen, Ronald C. , Petersen, Ronald C

Mayo Clinic

Annals of Neurology | October 26, 2021 | Volume: 90 | Issue: 6 | Pages: 1004-1004

10.1002/ana.26253 | PMID 34699091 Get It

Kinematic Analysis of Lateral Meniscal Oblique Radial Tears in the Anterior Cruciate Ligament–Deficient Knee
Smith, Patrick A. , Bezold, Will , Cook, Cristi R. , Krych, Aaron J. , Krych, Aaron J , Stuart, Michael J. , Wijdicks, Coen A. , Cook, James L.

Mayo Clinic

The American Journal of Sports Medicine | October 26, 2021 | Volume: 49 | Issue: 14 | Pages: 3898-3905

10.1177/03635465211052521 | PMID 34699272 Get It

Background: Lateral meniscal oblique radial tears (LMORT) occur frequently in conjunction with anterior cruciate ligament (ACL) disruption and are anatomically distinct from meniscus root tears. Hypothesis/Purpose: The purpose of this study was to characterize the effects of LMORT types 3 (LMORT3) and 4 (LMORT4) lesions on joint stability and meniscal extrusion in ACL-deficient knees. Our hypothesis was that both lesions would promote significant increases in anterior translation and meniscal extrusion, with the LMORT4 lesion having a greater effect. Study Design: Controlled laboratory study. Methods: Two matched pairs of cadaveric knees (n = 4) were used to optimize the testing sequence. Additional cadaveric knees with LMORT3 (n = 8) and LMORT4 (n = 8) lesions created after ACL transection underwent robotic kinematic testing for anterior drawer and pivot-shift simulations with associated ultrasound-measured meniscal extrusion at clinically relevant knee flexion angles. Results: Optimization testing showed no differences on the effect of LMORT4 lesions for anterior translation and lateral meniscal extrusion with ACL-intact versus ACL-deficient knees. ACL deficiency and LMORT3 and LMORT4 lesions with ACL deficiency were associated with significantly greater anterior translation compared with ACL-intact state for both anterior drawer and pivot-shift testing at all flexion angles ( P < .001). ACL deficiency with either LMORT3 or LMORT4 lesion was associated with significantly greater anterior translation than was ACL deficiency only ( P < .005) for anterior drawer testing at 90° of flexion. Meniscal extrusion was greater with LMORT3 and LMORT4 lesions compared with ACL deficiency only ( P < .05) for anterior drawer at 60° of flexion and for pivot shift at 15° of flexion. The LMORT4 lesion demonstrated increased anterior translation for anterior drawer ( P = .003) at 60° of flexion (12%) as well as for pivot shift at 15° of flexion (7%) and 30° of flexion (13%) ( P < .005) compared with ACL deficiency only. Conclusion: In this cadaveric model, the addition of an LMORT3 or LMORT4 lesion increased anterior laxity for both the anterior drawer and the pivot shift when compared with an isolated ACL tear. Lateral meniscal extrusion was also exacerbated by these LMORT lesions. Clinical Relevance: LMORT lesions, distinct from meniscus root tears, occur frequently in conjunction with ACL tears. This study characterized the biomechanical consequences of LMORT3 and LMORT4 lesions on joint stability and meniscal function, highlighting the importance of diagnosing and treating LMORT lesions at the time of ACL reconstruction.
Population-based incidence and time to classification of systemic lupus erythematosus by three different classification criteria: a Lupus Midwest Network (LUMEN) study
Duarte‐García, Alí , Hocaoǧlu, Mehmet , Osei‐Onomah, Shirley‐Ann, Dabit, Jesse Y. , Giblon, Rachel , Helmick, Charles G. , Crowson, Cynthia S. , Giblon, Rachel E., Duarte-García, Alí

Mayo Clinic

Rheumatology | October 26, 2021 | Volume: 61 | Issue: 6 | Pages: 2424-2431

10.1093/rheumatology/keab807 | PMID 34718442 Get It

AbstractObjectiveTo estimate the incidence and time-to-classification of SLE by the 1997 ACR (ACR97) criteria, the SLICC criteria, and the European Alliance of Associations for Rheumatology/ACR (EULAR/ACR) criteria.MethodsWe identified all incident SLE cases from 2000–2018 in the well-defined Olmsted County population. Clinical data included in the ACR97, SLICC and EULAR/ACR criteria were manually abstracted from medical records. All incident cases met at least one of the three classification criteria. Time-to-classification was estimated from the first documented lupus-attributable disease manifestation to the time of criteria fulfilment by each of the three definitions. Annual incidence rates were age or age/sex adjusted to the 2000 US population.ResultsOf 139 incident cases there were 126 cases by the EULAR/ACR criteria, corresponding to an age/sex-adjusted incidence of 4.5 per 100 000 population (95% CI: 3.7, 5.2). The age/sex-incidence was higher than that of the SLICC criteria (113 cases; 4.0 per 100 000 [95% CI: 3.3, 4.7], P = 0.020) and the ACR97 (92 cases; 3.3 per 100 000 [95% CI: 2.6, 3.9], P &lt; 0.001). The median time from first disease manifestation to criteria fulfilment was shorter for the EULAR/ACR criteria (29.4 months) than the ACR97 criteria (47.0 months, P &lt; 0.001) and similar to the SLICC criteria (30.6 months, P = 0.83).ConclusionThe incidence of SLE was higher by the EULAR/ACR criteria compared with the ACR97 and the SLICC criteria, and the EULAR/ACR criteria classified patients earlier that the ACR97 criteria but similar to the SLICC criteria.
Efficacy of empiric antibiotic management of septic olecranon bursitis without bursal aspiration in emergency department patients
Beyde, Adrian , Thomas, Alexa , Colbenson, Kristina M., Sandefur, Benjamin J. , Kisirwan, Imtithal, O’Driscoll, Shawn W. , Thomas, Alexa L, O'Driscoll, Shawn W., Campbell, Ronna L. , Fitzsimmons, James S , Thomas, Alexa L , Mullan, Aidan F.

Mayo Clinic

Academic Emergency Medicine | October 26, 2021 | Volume: 29 | Issue: 1 | Pages: 6-14

10.1111/acem.14406 | PMID 34698411 Get It

AbstractObjectivesMany guidelines for septic olecranon bursitis recommend aspiration of the bursa prior to initiation of antimicrobial therapy despite the absence of robust clinical data to support this practice and known risk of aspiration complications. Our objective was to describe outcomes associated with empiric antibiotic therapy without bursal aspiration among emergency department (ED) patients with suspected septic olecranon bursitis.MethodsWe conducted a retrospective observational cohort study of patients presenting to an academic ED from January 1, 2011, to December 31, 2018, with olecranon bursitis. The health record was reviewed to assess patient characteristics and outcomes within 6 months of the ED visit. Olecranon bursitis was considered “suspected septic” if the patient was treated with antibiotics. The primary outcome of interest was complicated versus uncomplicated bursitis resolution. Uncomplicated resolution was defined as bursitis resolution without subsequent bursal aspiration, surgery, or hospitalization.ResultsDuring the study period, 264 ED patients were evaluated for 266 cases of olecranon bursitis. The median age was 57 years and 85% were men. Four (1.5%) patients had bursal aspiration during their ED visit, 39 (14.7%) were admitted to the hospital, 76 (28.6%) were dismissed without antibiotic therapy, and 147 (55.3%) were dismissed with empiric antibiotic therapy for suspected septic olecranon bursitis. Among these 147 patients, 134 had follow‐up available including 118 (88.1%, 95% confidence interval [CI] = 81.1%–92.8%) with an uncomplicated resolution, eight (6.0%, 95% CI = 2.8%–11.8%) who underwent subsequent bursal aspiration, and nine (6.7%, 95% CI = 3.3%–12.7%) who were subsequently admitted for inpatient antibiotics.ConclusionsEighty‐eight percent of ED patients with suspected septic olecranon bursitis treated with empiric antibiotics without aspiration had resolution without need for subsequent bursal aspiration, hospitalization, or surgery. Our findings suggest that empiric antibiotics without bursal aspiration may be a reasonable initial approach to ED management of select patients with suspected septic olecranon bursitis.